News Updates
Scope

Mon, May 18, 2026

1 updates
WVE
4:30 PM

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated approval pathway mid-2026

Interim Data • Phase 1/2Interim data Mon, May 18, 2026wavelifesciences.com

Wed, May 13, 2026

1 updates

Tue, Apr 28, 2026

1 updates
WVE
7:30 AM

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track

Results Call • Phase 1/2Call Mon, May 18, 2026, 5:30 PM ETwavelifesciences.com

Wed, Apr 22, 2026

1 updates

Tue, Apr 21, 2026

1 updates

Wed, Apr 15, 2026

1 updates
WVE
4:01 PM

Wave Life Sciences Announces Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to

wavelifesciences.com

Thu, Mar 26, 2026

1 updates

Thu, Mar 5, 2026

1 updates
WVE
8:30 AM

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Presentation / Abstractwavelifesciences.com